Skip to main content

Main menu

  • Pipeline
    • Clinical
    • Discovery
    • Compounds
    • Regimens
    • Drug Targets
    • Developers
    • Trial Sites
    • Trials
  • News
  • Meetings
  • Members
    • Our Members
    • Core Group
  • About
  • Join Us
Regimen

Bedaquiline, Pretomanid, Moxifloxacin, Pyrazinamide

Compounds in Regimen
Bedaquiline
Pretomanid
Moxifloxacin
Pyrazinamide
Description

Currently under investigation in the SimpliciTB Trial. Click associated trial link for more details. 

Related Links
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients. ClinicalTrials.gov Identifier: NCT03338621
A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (
EFFICACY OF BEDAQUILINE, PRETOMANID, MOXIFLOXACIN & PZA (BPAMZ) AGAINST DS- & MDR-TB
Fact Sheet
Trial Associations
SimpliciTB
NC-005
Developer Associations
TB Alliance
  Would you like to receive updates from the WGND? Join our mailing list:
Interests

About Us

Part of Stop TB Partnership, we are a network of committed individuals devoted to accelerating the development of effective, affordable new therapies for TB.

Visit the Stop TB Partnership
Read about The Global Plan to End TB

Navigate

  • Clinical Pipeline
  • Discovery
  • Developers
  • Trials
  • Trial Sites
  • News
  • Meetings
  • Core Group
  • Members
  • About

Contact

The Working Group for New TB Drugs

80 Pine Street, Fl 20th
New York, NY

Contact Us

Follow Us

©2016 Working Group on New TB Drugs. All Rights Reserved. Terms of Reference Site by Darby Communications